Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.

Sharma SK, Solanki R, Mohan A, Jain NK, Chauhan LS; Pleural Effusion Study Group..

Int J Tuberc Lung Dis. 2012 Nov;16(11):1505-9. doi: 10.5588/ijtld.12.0233.

PMID:
23044446
2.

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.

Cochrane Database Syst Rev. 2013 Jul 5;(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Review.

PMID:
23828580
3.
4.

Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.

Kumar L, Gupta R, Puri MM, Jaiswal A, Srinath, Murar A, Behera D.

J Assoc Physicians India. 2011 Nov;59:733-5. Review.

PMID:
22616343
5.

Treatment of latent tuberculosis infection: An update.

Lobue P, Menzies D.

Respirology. 2010 May;15(4):603-22. doi: 10.1111/j.1440-1843.2010.01751.x. Epub 2010 Apr 7. Review.

PMID:
20409026
6.

Present status of chemotherapy for tuberculosis.

Grosset JH.

Rev Infect Dis. 1989 Mar-Apr;11 Suppl 2:S347-52. Review.

PMID:
2652251
7.

Treatment of childhood tuberculosis.

Vijayasekaran D.

Indian J Pediatr. 2011 Apr;78(4):443-8. doi: 10.1007/s12098-010-0273-0. Epub 2010 Oct 29. Review.

PMID:
21049292

Supplemental Content

Support Center